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Abstract Quality of life (QoL) is decreased in patients with
Fabry disease (FD). To improve QoL, it is important to under-
stand the influence of FD related characteristics, symptoms,
and complications. In this retrospective cohort study we ex-
plored the effect of pain (measured by the Brief Pain
Inventory), phenotype, treatment, and FD-related complica-
tions on QoL. QoL data of Fabry patients as assessed by the
EuroQol five dimension questionnaire (EQ-5D) from two in-
ternational centers of excellence were collected. The aim of
this study was to evaluate the effect of sex, phenotype, age,
different states of disease severity, pain, and ERT on EQ-5D
utilities. For 286 adult FD patients (mean age 42.5 years, 40%
men, 60% classical phenotype) 2240 EQ-5Ds were available.
QoL is decreased in men as well as women with FD, especial-
ly in older men with a classical phenotype. At age 50, utility
was lower in men with classical FD compared to those with
non-classical disease (β = −0.12, 95% CI: -0.23 – 0.01,
p = 0.037) with further difference in the years thereafter.
Cardiovascular complications, stroke or transient ischemic at-
tacks, multiple FD-related complications and pain were also
associated with decreased utilities. Overall, no change in util-
ity was seen in patients on ERT over a mean follow-up of
6.1 years. FD leads to a decreased QoL compared to the gen-
eral population. Disease complications and pain both nega-
tively influence QoL. Adequate assessment and treatment of
pain as well as improved strategies to prevent disease compli-
cations are needed to improve QoL in the FD population.
Introduction
Fabry disease (FD; OMIM 301500) is a rare X-linked lysosom-
al storage disorder with a heterogeneous disease course. The
disease is caused by a deficiency of the enzyme α-
galactosidase A (enzyme commission no. 3.2.1.22) due to mu-
tations in the GLA-gene. This results in accumulation of
globotriaosylceramide (Gb3) and related sphingolipids in cells
throughout the body and may cause clinical complications,
especially in kidney, heart, and brain. Despite the X-linked
inheritance pattern, women are affected as well, and may de-
velop similar symptoms and complications as men
(MacDermot et al 2001a; Mehta et al 2004). Both men and
women with FD experience a decreased QoL (Street et al
2006; Wang et al 2007; Wilcox et al 2008; Arends et al 2015).
Phenotypically, FD can be divided into classical or non-
classical disease. Men with classical FD generally have no
residual enzyme activity and often exhibit Fabry-specific
symptoms including neuropathic pain, cornea verticillata,
and angiokeratoma. Men with non-classical FD and women
with either classical or non-classical FD have residual en-
zyme activity, usually resulting in a milder disease course.
Older studies showed severely decreased QoL, predominant-
ly in men who nowadays most likely would be considered to
Maarten Arends and Simon Körver contributed equally
Communicated by: Markus Ries
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s10545-017-0095-6) contains supplementary
material, which is available to authorized users.
* Carla E. M. Hollak
c.e.hollak@amc.uva.nl
1 Department of Endocrinology and Metabolism, Academic Medical
Center, Meibergdreef 9, 1105, AZ Amsterdam, The Netherlands
2 Department of Haematology, Royal Free London NHS Foundation
Trust, London, UK
3 Department of Haematology, University College London,
London, UK
J Inherit Metab Dis
DOI 10.1007/s10545-017-0095-6
have classical FD (Gold et al 2002; Miners et al 2002). Also
in more recent studies a distinction in phenotypes has not
been made. In other words, the effect of phenotype on QoL
has yet to be elucidated.
Part of the decreased QoL in patients with FD seems to be
associated with the neuropathic pain often seen in men with
classical FD (Gold et al 2002). Episodes of severe, debilitating
burning pains can be alternated with chronic pain, mostly in
hands and feet. Moreover, the presence of gastro-intestinal
(GI) symptoms, including GI-pain, is also associated with
lower QoL (Hoffmann et al 2007). Several studies reported a
positive effect of enzyme replacement therapy (ERT) on pain
(Schiffmann et al 2001; Hoffmann et al 2005;Watt et al 2010).
In contrast, no clear effect of ERTon QoL was established in a
recent systematic review from our group (Arends et al 2015).
Besides pain, complications linked to FD such as end stage
renal disease (ESRD), cardiomyopathy, and stroke have been
associated with decreased QoL (Gold et al 2002; Miners et al
2002; Wagner et al 2014). For the purpose of a cost-
effectiveness analysis, Rombach et al created mutually exclu-
sive disease states to simulate the disease course of FD
(Rombach et al 2013a). Lower QoL was found in patients in
a more severe disease state. However, the sample size neces-
sitated grouping of different complications in one single
group, so the effect of individual cerebral, renal or cardiac
complications on QoL remained unknown. Better understand-
ing of QoL in different disease states and improved under-
standing of the influence of specific symptoms and complica-
tions on QoL may facilitate targeted treatment, and thereby
improve the well-being of Fabry patients. With this study we
aim to gain insight into the influence of sex, phenotype, age,
disease severity, and ERT on QoL.
Methods
Study design
Using local databases containing prospectively collected data
as well as medical records, demographic, clinical, and labo-
ratory data of all FD patients from two centers of excellence
(Academic Medical Center (AMC), The Netherlands; and
Royal Free London NHS Foundation Trust (RFH), United
Kingdom) were merged into one database. This cohort repre-
sents part of a larger study (Arends et al 2016) with available
EuroQol five dimension questionnaire (EQ-5D) data. Baseline
was defined as the date of the first EQ-5D measurement, ex-
cept for the evaluation of the influence of ERT on the QoL
where the start date of ERT was used as baseline.
According to Dutch law, and after review of the AMC
ethics committee, no approval of the study protocol was need-
ed because of the observational nature of the study. All data
were obtained from medical records. Patient records were
anonymized and de-identified prior to analysis. All patients
have provided consent for the use of their medical data and
samples in accordance with local ethics requirements.
Study participants
Adult patients (≥18 years) with a definite FD diagnosis ac-
cording to previously developed criteria (Smid et al 2014) of
whom sufficient data for phenotypical classification and one
or more EQ-5D measurements were available, were included.
They were categorized as classical or non-classical on the
basis of enzyme activity and the presence or absence of char-
acteristic FD symptoms (Fabry neuropathic pain, clustered
angiokeratoma and/or cornea verticillata (van der Tol et al
2014)). A detailed description of the classification method
has been published earlier (Supplement A, (Arends et al
2016)).
EQ-5D
The EQ-5D is a QoL questionnaire that covers five different
QoL domains: mobility, self-care, anxiety/depression, usual
activities, and pain/discomfort (EuroQol-Group 1990).
Respondents are asked to choose per domain which one of
the following three options describes their situation best: no
problems, some/moderate problems or extreme problems
(Rabin and de Charro 2001). EQ-5D data can be presented
as a health profile which shows the frequency of reported
problems for each level for each dimension (Rabin and de
Charro 2001). Also, a utility for the health status can be cal-
culated by combining the responses on all five domains. A
utility of 1 means perfect health and a score of 0 represents
death. Negative scores can also be obtained representing
health states that are considered worse than death. Utilities
differ per country. For our study we used the Dutch and UK
weighing for Dutch and English patients, respectively (Dolan
1997; Lamers et al 2005).
Pain assessment
The AMC and the RHF both used the Brief Pain Inventory
(BPI) to assess the presence and severity of pain and its influ-
ence on daily life. All BPI scores closest to the utility with a
maximum window of ±3 months were used. The BPI assesses
pain at its worst, average pain, and pain interference with life.
The interference score measures the influence of pain on gen-
eral activity, walking, work, mood, enjoyment of life, relations
and sleep. It is the mean of at least four of these items. Worst
pain, average pain, and the interference score are graded from
0 (pain is absent) to 10 (worst possible pain) (Cleeland and
Ryan 1994).
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Disease severity
To evaluate the effect of symptoms, organ involvement, and
complications in FD, patients were classified in ten mutually
exclusive disease states with increasing severity (Rombach
et al 2013a) (Table 1). According to strict criteria, patients
can transition from one state to another in case of disease
progression.
Clinical and laboratory measurements
Renal function was evaluated by the estimated glomerular
filtration rate (eGFR) using the CKD-EPI formula (Kidney
Disease: Improving Global Outcomes (KDIGO) CKD Work
Group 2013) and proteinuria. Cardiac involvement was
assessed by echocardiography. Left ventricular mass (LVM)
was calculated using the Devereux formula and was corrected
for height (m2.7) (Lang et al 2005). Left ventricular hypertro-
phy was defined as LVM ≥49 and ≥45 g/m2.7 in men and
women, respectively (Lang et al 2005). The presence of white
matter lesions (WMLs)/ischemic lesions was investigated by
cerebral MRI. Plasma lysoGb3 levels were measured with
tandem mass spectrometry with glycine labeled (RFH and
AMC after August 2015) or isotope labeled lysoGb3 (AMC
before August 2015) as an internal standard (Gold et al 2013;
Arends et al 2016).
Statistical methods
R (version 3.1.5) and SPSS for Windows, version 22.0 (SPSS
Inc. Chicago, Illinois, USA) were used. First, utilities per sex
and phenotype were calculated, followed by a second order
polynomial regression mixed effect model with a random in-
tercept and slope to evaluate the effect of age on utilities,
stratified for sex and phenotype. To evaluate the relation be-
tween BPI score and utility, the polynomial mixed effect mod-
el was extended by including BPI scores as covariate.
Second, the effect of ERTon utilities was investigated with
a linear mixed model including time on ERT and age at ERT
initiation as time-dependent covariates and a mixed model of
the difference between the utility at baseline and follow up
measurements. Since QoL is known to fluctuate over time,
patients were only included in this analysis if they completed
an EQ-5D within 3 months before the start of ERT. Finally,
utilities per disease state for the combined cohort of men and
womenwith classical and non-classical disease weremodeled.
To account for the fact that one patient may have filled in more
than one EQ-5D per disease state, a linear mixed effect model
Table 1 Description of disease
states Disease state* Description
Asymptomatic
No organ involvement No left ventricular hypertrophy, kidney disease, white matter lesions or
complications
Symptoms
Neuropathic pain A history of Fabry neuropathic pain in the extremities provoked by heat,
fever or exercise (also referred to as acroparesthesia)
Organ involvement Left ventricular hypertrophy, chronic kidney disease stages 2–4,
albuminuria/proteinuria or white matter lesions
Single complication
End stage renal disease Chronic kidney disease stage 5 (eGFR < 15 ml/min/1.73m2), dialysis
or kidney transplant
Cardiac complication(s) Atrial fibrillation, any other rhythm disturbance needing hospitalization,
pacemaker or implantable cardiac defibrillator (ICD) implantation,
cardiac congestion for which hospital admittance was needed,
myocardial infarction, percutaneous coronary intervention or coronary
artery bypass graft
Cerebrovascular accident Transient ischemic attack (TIA) or stroke, as diagnosed by a neurologist
Multiple complications#
End stage renal disease and cardiac complication(s)
End stage renal disease and cerebrovascular accident
Cardiac complication(s) and cerebrovascular accident
End stage renal disease and cardiac complication(s) and cerebrovascular accident
*Typically, patients progress from the asymptomatic state or neuropathic pain state to the symptoms state; from
the symptoms state to a single complication state; from a single complication state to a double complication state,
and from a double complication state to the triple complication state
# Since the number of patients in the disease states representing more than one complication was low, one
combined ‘multiple complications’ disease state was made
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with the disease state as covariate and a random intercept was
used to evaluate the utility per disease state. Patient numbers
were too small to include sex and phenotype. In order to an-
alyze the effect of eGFR, LVM, and WML on QoL within the
Borgan involvement^ disease state, univariate, and multivari-
ate analyses were performed within this group. Data are pre-
sented as mean ± standard deviation (SD) or median and range
dependent on the distribution of data.Where appropriate, 95%
confidence intervals (95% CI) are given. P-values <0.05 were
considered statistically significant.
Results
The merged database contained data on 439 patients from the
AMC and the RFH, of whom 27 patients did not fulfill the
criteria for a definite diagnosis, 12 had insufficient baseline
data for assessment of disease severity and no follow-up data,
and 114 patients did not complete one or more EQ-5D mea-
surements. Two-hundred-eighty-six FD patients (117 patients
from the AMC and 169 patients from the RFH) with a mean
age: 42.5 ± 12.5 years completed 2240 EQ-5Ds. Each patient
completed on average 7.8 ± 4.5 EQ-5Ds during a mean
follow-up period of 5.4 ± 3.2 years. Classically affected pa-
tients completed more EQ-5Ds compared to non-classically
affected patients. Table 2 shows the baseline characteristics at
the time of completion of the first EQ-5D.
Health profile at baseline per phenotype and per disease
state
The health profile of the first completed EQ-5D (Table 3)
shows that 35.5% of all men with classical FD reported
some/moderate problems of mobility with one patient
reporting extreme problems. Lower percentages (21.9% to
28.9%) of women and men with non-classical disease report-
ed some/moderate mobility problems. Self-care was relatively
preserved in all subgroups of patients, while 35.3% experi-
enced some/moderate problems with their usual activities with
percentages ranging from 25.0% in women with non-classical
FD to 42.1% in men with classical disease. Twenty-one pa-
tients (7.3%) experienced extreme pain at baseline and almost
two-thirds of the men with classical FD experienced at least
some/moderate pain. Some/moderate anxiety or depressive
symptoms were noted in about one third of men with classical
FD and women with classical and non-classical FD. The
health profiles of the first EQ-5D per disease state
(Supplemental Table B) indicated that a large proportion of
patients in the ‘neuropathic pain’ disease state reported prob-
lems with their usual activities and anxiety/depression do-
main, and some/moderate to extreme problems in the pain/
discomfort domain. Since the number of patients in the dis-
ease states representing more than one complication was low,
one combined ‘multiple complications’ disease state was
made, representing patients with complications in at least
two organs (kidney, heart and/or brain). Patients in the ‘single’
and ‘multiple complication’ disease states reported problems
across all domains.
Relation between phenotype, age, and utilities
Adecrease in utilities with age was seen in all subgroups (Fig. 1),
although the extent of this relation differed between the sub-
groups. The mixed model revealed that the utility of a 50-year-
old man with classical FD is on average 0.12 points lower (95%
CI: -0.23 – 0.01, p= 0.037) compared to amanwith non-classical
FD of the same age. At age 60 this mean difference has increased
to 0.21 points (95% CI: -0.36 – -0.07, p = 0.004). This illustrates
the progressive worsening of utilities in men with classical FD
with increasing age. In women and men with non-classical FD
the decline in utilities with age was less strong (Fig. 1).
Relation between BPI scores and utilities
In total 1559 BPIs of 276 patients were matched to an EQ-5D.
Of the patients that completed BPIs 45.3% were men, 61.2%
had the classical phenotype, and the mean age was
44.8 ± 14.9 years. Utilities decreased with higher BPI scores:
with every one point higher BPI average pain score, the utility
decreased on average by 0.045 points (β = −0.045, 95% CI: -
0.049 – -0.040, p < 0.001). Similarly, an increase in BPI worst
pain score (β = −0.035, 95%CI: -0.039 – -0.031, p < 0.001) or
BPI interference score (β = −0.058, 95% CI: -0.063 – -0.053,
p < 0.001) resulted in lower utilities. A sensitivity analysis
without the pain/discomfort domain in the calculation of the
utilities did not change the results.
The effect of ERT on utilities
For the evaluation of the effect of ERT on utilities, 61 patients
were analyzed who completed at least one EQ-5D before the
initiation of ERT. The mean age of patients at ERT initiation
was 44.2 ± 15.5 years, and the mean follow-up time after
initiation of ERTwas 6.1 ± 2.5 years. The median utility score
before ERT was 0.796 (−0.166–1.000). Utility remained un-
changed after start of treatment (β = −0.004, 95% CI: -0.066 –
0.058, p = 0.89). Furthermore, there was no relation between
change in utility, time on ERT (β = −0.005, 95% CI: -0.016 –
0.006, p = 0.40) and age at ERT initiation (β = −0.002, 95%
CI: -0.006 – 0.001). In a subgroup analysis, we found that
utilities increased after initiation of ERT in the 13 men with
classical FD (β = 0.17, 95% CI: 0.0 6– 0.28, p = 0.003). This
was primarily attributable to three patients with a very low
utility before the start of ERT due to extreme pain/discomfort
which improved substantially after the start of treatment. One
of them started taking carbamazepine for his neuropathic pain
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during the same period, leading to a substantial decrease in
neuropathic pain in the months thereafter. Without these three
patients no change in utility was observed (β = 0.04, 95% CI: -
0.07 – 0.14, p = 0.50). Additional subgroup analyses revealed
that no annualized change in utility was observed in women
with classical or non-classical disease, while in men with non-
classical FD a 0.027 point decline per year on ERT (95% CI: -
0.053 – 0.001, p = 0.04) was found.
Relation between disease severity and utilities
Table 4 shows the mean utility per disease state for men and
women with classical and non-classical FD combined. Within
the Borgan involvement^ disease state we found no relation
between eGFR, LVMI, and WML on the one hand and utili-
ties on the other hand. Patients included in the advanced dis-
ease states, and thus with more severe disease, were older and
more often men with classical FD. Compared to the ‘no organ
involvement’ disease state, the utilities were significantly low-
er in the ‘cardiac complication(s)’, ‘cerebrovascular accident’,
and the ‘multiple complications’ disease states but not the
‘end stage renal disease’ disease state. The utility of the latter
was based on a low number of patients (n = 7) who showed
divergent utility scores. The lowest utility was found in the
‘multiple complications’ disease state (β = 0.530, 95% CI:
0.42–0.63). The ‘neuropathic pain’ disease state also showed
a trend toward lower utility compared to the ‘no organ in-
volvement’ disease state (p = 0.053).
Table 2 Characteristics of all patients at first EQ-5D measurement
All Men Women
Classical Non-classical Classical Non-classical
Patients, n (%) 286 76 (26.6) 38 (13.3) 96 (33.6) 76 (26.6)
Age in years, mean (±SD) 42.5 (±15.5) 37.4 (±12.5) 54.2 (±15.4) 44.0 (±15.5) 40.7 (±15.2)
Age first visit, mean (±SD) 40 (±16.0) 34.2 (±12.5) 52.8 (±15.8) 42.6 (±15.6) 37.8 (±15.5)
History of ERT, n (%) 125 (43.7) 57 (75.0) 13 (34.2) 41 (42.7) 14 (18.4)
Currently on ERT, n (%) 117 (40.9) 52 (68.4) 13 (34.2) 39 (40.6) 13 (17.1)
Time on ERT in years, mean (±SD) 2.97 (±2.38) 3.69 (±2.61) 1.94 (±2.03) 2.73 (±2.05) 1.87 (±1.89)
Events before first EQ-5D
Any event, n (%) 50 (17.5) 16 (21.1) 14 (36.8) 16 (16.7) 4 (5.3)
Cardiac event, n (%) 33 (11.5) 8 (10.5) 12 (31.6) 9 (9.4) 4 (5.3)
Renal event, n (%) 8 (2.8) 5 (6.6) 2 (5.3) 1 (1.0) 0 (0)
Cerebral event, n (%) 20 (7.0) 8 (10.5) 3 (7.9) 9 (9.4) 0 (0)
WML, n (%) 112 (39.2) 34 (44.7) 11 (28.9) 41 (42.7) 26 (34.2)
eGFR in ml/min/1.73m2, mean (±SD) 93.8 (±25.9) 99.0 (±30.3) 80.6 (±26.3) 96.7 (±21.6) 91.5 (±23.7)
eGFR <60 ml/min/1.73m2, n (%) 29 (10.3) 10/76 (13.2) 6/38 (15.8) 5/94 (5.3) 8/73 (11.0)
LVM in gr/m2.7, median (range) 42.0 (16.2–139.9) 48.3 (23.6–110.4) 54.2 (16.2–99.9) 40.8 (18.2–139.9) 34.5 (17.1–96.2)
LVM > upper ref. limit, n (%) 101 (37.4) 33/74 (44.6) 20/35 (57.1) 32/92 (34.8) 16/69 (23.2)
LysoGb3* in nmol/L, median (range) 7.5 (0.4–150.3) 105.5 (31.8–150.3) 6.0 (1.2–22.4) 7.6 (0.7–27.2) 2.0 (0.4–15.4)
BPI average pain*, median (range) 2 (0–8) 2 (0–8) 0 (0–7) 3 (0–8) 3 (0–8)
BPI worst pain*, median (range) 3 (0–10) 3 (0–10) 0 (0–9) 3 (0–9) 3 (0–10)
BPI average interference*, median (range) 0.6 (0–9.9) 0.5 (0.0–8.4) 0.1 (0.0–9.9) 0.5 (0.0–9.3) 1.1 (0.0–9.7)
EQ-5Ds#, n 2240 668 286 771 515
EQ-5Ds per patient#, mean (±SD) 7.8 (±4.5) 8.8 (±4.8) 7.5 (±4.1) 8.2 (±4.5) 6.8 (±4.4)
Follow-up time#, mean (±SD) 5.38 (±3.15) 5.73 (±3.46) 4.71 (±2.86) 5.56 (±2.98) 5.13 (±3.15)
Events represent the number of patients with one or more events before first EQ-5D. Events were defined as described at end stage renal disease, cardiac
complications, and cerebrovascular accident similar to the definition of the disease states (Table 1)
ERT, enzyme replacement therapy;WML, white matter lesions on MRI; eGFR, estimated glomerular filtration rate; LVM, left ventricular mass index on
echocardiography; BPI, Brief Pain Inventory
Upper reference limit LVM: ♂ = 51 / ♀ = 48. Normal range lysoGb3 = 0.3–0.6 nmol/L. LysoGb3 represents values before start of ERT.
*Values missing: LysoGb3 32%, BPI average pain 16%, BPI worst pain 15%, BPI average interference 12%
#Values acquired during follow-up
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Table 3 Health profile and utility
of the first EQ-5D measurement
stratified for sex and phenotype
All Men Women
Classical Non-classical Classical Non-classical
Mobility Number of patients (%)
1* 207 (72.4) 48 (63.2) 27 (71.1) 75 (78.1) 57 (75.0)
2 78 (27.3) 27 (35.5) 11 (28.9) 21 (21.9) 19 (25.0)
3 1 (0.3) 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
Self-care Number of patients (%)
1 261 (91.3) 64 (84.2) 34 (89.5) 93 (96.9) 70 (92.1)
2 22 (7.7) 10 (13.2) 4 (10.5) 3 (3.1) 5 (6.6)
3 3 (1.0) 2 (2.6) 0 (0.0) 0 (0.0) 1 (1.3)
Usual activities Number of patients (%)
1 173 (60.5) 40 (52.6) 25 (65.8) 57 (59.4) 51 (67.1)
2 101 (35.3) 32 (42.1) 12 (31.6) 38 (39.4) 19 (25.0)
3 12 (4.2) 4 (5.3) 1 (2.6) 1 (1.0) 6 (7.9)
Pain/discomfort Number of patients (%)
1 138 (48.3) 29 (38.2) 22 (57.9) 47 (49.0) 40 (52.6)
2 127 (44.4) 43 (56.6) 15 (39.5) 40 (41.7) 29 (38.2)
3 21 (7.3) 4 (5.3) 1 (2.6) 9 (9.4) 7 (9.2)
Anxiety/depression Number of patients (%)
1 191 (66.8) 51 (67.1) 27 (71.1) 65 (67.7) 48 (63.2)
2 90 (31.5) 25 (32.9) 9 (23.7) 31 (32.3) 25 (32.9)
3 5 (1.7) 0 (0.0) 2 (5.3) 0 (0.0) 3 (3.9)
Utility#, mean (±SD) 0.77 (±0.26) 0.75 (±0.25) 0.81 (±0.27) 0.79 (±0.23) 0.76 (±0.30)
*1 = no problems, 2 = some/moderate problems, 3 = extreme problems
# Please note that a baseline utility is presented in contrast to Fig. 1 which presents longitudinal utilities
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Fig. 1 Relation between EQ-5D and age. Polynomial mixed effect model of EQ-5D in relation to age, stratified for sex and phenotype. Large lines
represent fitted values at group level, the smaller lines represent the fitted values at individual patient level
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Discussion
This study shows that QoL in patients with FD is related to
phenotype, age, pain, and disease severity. Obviously, these
features are related to each other; classically affected patients
of older age will have more severe disease with a higher chance
of developing FD-related complications and thus a decreased
QoL. Additional analyses to study the independent effects of
these features on QoL were not feasible due to limited patient
numbers and the expectation of high multicollinearity.
The mean utility of FD patients in the present study ranged
from 0.75 in men with classical FD to 0.81 in men with non-
classical disease, and QoL decreased with advancing age.
Comparison of the health profile of these patients to the health
profile of the general population in the UK and the
Netherlands supports a higher prevalence of impaired QoL
in FD (Supplemental Table C) (Kind et al 1998; Lamers
et al 2006). In line with the current results, a recent study in
a mixed cohort of treated and untreated men and women with
FD showed a mean utility of 0.79 (Żuraw et al 2011).
In contrast, a cohort study from the pre-ERT era in which
38 men of similar age and with presumed classical disease
were included, showed a substantially lower utility of 0.56
(Miners et al 2002). These patients had more often suffered
from one or more complications (Miners et al 2002).
Therefore, a possible explanation for the difference in utilities
is that in our cohort ERT delayed the occurrence of complica-
tions and therefore delayed the decrease in QoL caused by
complications (Rombach et al 2013b). Indeed, in a recent
study from our group on the natural course of FD stratified
by sex and phenotype, men with classical disease were shown
to have the highest risk of developing complications (Arends
et al 2016). The median age at first complication was approx-
imately 50 years, which corresponds with the age after which
the decrease in QoL accelerates in these men in the present
study. The fact that the utility in the pre-ERTcohort resembles
the utility in our ‘multiple complications’ disease state further
supports this. It is unlikely that QoL scores in the investigated
FD populations are influenced by regional differences, since
the QoL scores in the general population in the UK and the
Netherlands are comparable (Supplemental Table C).
However, other factors may have contributed to the higher
QoL in the present study compared to the pre-ERT cohort,
such as pain management. Indeed, a detailed look at the health
profiles of the different subgroups of patients indicates that the
prevalence of extreme pain seems to have decreased when
compared to older studies (Supplemental Table C) (Miners
et al 2002; Hoffmann et al 2005). However, pain is still present
in around half of the patients and associatedwith lower QoL in
FD, as also established in a Fabry Outcome Survey study
(Hoffmann et al 2005). Moreover, chronic pain is related to
decreased QoL in all domains in the general population
(O’Brien and Breivik 2012). Therefore, QoL is expected toTa
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increase if pain control is improved. An often mentioned
cause of pain in patients with FD is neuropathic pain in the
extremities (also called acroparesthesia), which is associated
with decreased QoL (Gold et al 2002). However, in this study,
men with non-classical FD and women, who are known to
have a low prevalence of Fabry-related neuropathic pain, also
frequently reported pain. Indeed, a previous study has shown
that other types of pain (e.g., musculoskeletal pain or GI-pain)
may play an important role in the life of FD patients (Uceyler
et al 2014). As a consequence, it is recommended to assess
individual causes of pain and manage it accordingly (Uceyler
et al 2014; Politei et al 2016; Schuller et al 2016).
The reported percentage of extreme anxiety/depression in
the health profile has also decreased compared to older studies
(Miners et al 2002; Hoffmann et al 2005). The availability of
treatment in itself can provide hope or relief of complaints and
might reduce anxiety/depressive complaints (Miller et al 2009).
On the other hand, in other metabolic diseases it has been spec-
ulated that biweekly infusions are burdensome, especially in the
hospital setting, thereby potentially affecting QoL (Angelini
2015; Gungor et al 2016). In our study, no effect of ERT was
seen on the percentage of patients with anxiety/depression.
Previous studies have not been able to unequivocally deter-
mine the effect of ERTon QoL (Arends et al 2015). The current
study showed that QoL did not change over 6 years of follow-
up in patients receiving ERT. However, there are individual
differences in the course of QoL with some patients deteriorat-
ing while others improve. Of interest to this end is the observa-
tion that three out of 13 men with classical FD had higher
utilities after start of ERT, especially in the pain and activity
domain. However, it is difficult to attribute the improvement in
QoL to the start of ERT, because pain may subside spontane-
ously (MacDermot et al 2001b; Biegstraaten et al 2012).
Moreover, we could not correct for concomitant analgesic or
antidepressant treatment that might improve or stabilize QoL.
In patients with deteriorating QoL, ERT may have been
started too late. Indeed, it has been previously shown that ERT
is of limited benefit in patients with advanced organ involvement
and complications (Rombach et al 2013b). In the present study
complications are clearly associated with a decreased QoL: ce-
rebrovascular accidents, cardiovascular complications, and mul-
tiple complications resulted in a decrease in utilities of 0.15, 0.12,
and 0.32 respectively, all exceeding the minimally clinically im-
portant difference of 0.074 (Walters and Brazier 2005).
Our study has several limitations. Firstly, the EQ-5D offers
three answer options per domain, limiting the detection of small
changes in health (Herdman et al 2011). Secondly, question-
naire data were gathered during clinical visits, in some patients
for up to 15 years in a row. Habituation to repeatedly filling out
a questionnaire as well as coping might have influenced the
questionnaire accuracy. Thirdly, the lack of a control group
hampered the interpretation of the effect of ERT on QoL.
Finally, since the QoL data were gathered in an uncontrolled,
real-life environment, they weremore prone to be influenced by
known and unknown confounders, such as presence of con-
comitant diseases and the use of pain medication. On the other
hand, real-life data provides an opportunity to assess QoL in
actual practice conditions. Despite these shortcomings an in-
sight has been gained into QoL in FD and its determinants,
which can be used to improve the care for these patients.
Conclusion
In conclusion, QoL is decreased in men as well as women
with FD compared to the general population, especially in
older men with a classical phenotype. QoL is lower in patients
with FD-related complications and ERT does not seem to have
a major impact on QoL. This necessitates the improvement of
treatment and preventive strategies. Pain also has a severe
impact on QoL. It is prevalent in both sexes and phenotypes
and comprises more than neuropathic pain alone. Pain assess-
ment should be an important part of routine follow-up and
treatment should be standardized and evaluated accordingly.
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